VivoSeq
Infectious Disease

Respiratory Syncytial Virus

12

Pipeline Programs↗

17

Active Trials↗

15

Companies Involved↗

Respiratory Syncytial Virus is an emerging landscape with 12 programs across 15 companies. The most active players are Moderna, Eli Lilly, GSK. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

84/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Moderna logo

Moderna

2 programs

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1GSK logo

GSK

17 programs

Phase 1Pfizer logo

Pfizer

2 programs

Phase 3Sanofi logo

Sanofi

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

RNA therapy

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule133%

RNA therapy leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 18% of 22 pipeline programs.

Analysis

Trial Status

61

clinical trials

Completed36 · 59%
Active, not recruiting10 · 16%
Terminated7 · 11%
Recruiting5 · 8%
Not yet recruiting2 · 3%
Unknown status1 · 2%

Clinical Trials

Trial Activity

61 trials

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Recruiting·GSK logoGSK·Phase 3·NCT07220109·750 enrolled
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above
Recruiting·SShenzhen Shenxin Biotechnology Co., Ltd·Phase 1·NCT06645665·240 enrolled
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Recruiting·MMAXVAX Biotechnology Limited Liability Company·Phase 3·NCT07272434·25,000 enrolled
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
Recruiting·SSinocelltech Ltd.·Phase 1/2·NCT06754605·480 enrolled
A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years
Recruiting·GSK logoGSK·Preclinical·NCT07628049·1,808 enrolled
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
Active, not recruiting·Moderna logoModerna·Phase 2·NCT06143046·360 enrolled
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
Active, not recruiting·GSK logoGSK·Phase 3·NCT06534892·10,212 enrolled
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
Active, not recruiting·GGuangzhou Patronus Biotech Co., Ltd.·Phase 2·NCT07208461·700 enrolled
Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above
Active, not recruiting·SSuzhou Abogen Biosciences Co., Ltd.·Phase 2·NCT07289542·420 enrolled
Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
Active, not recruiting·Sanofi logoSanofi·Phase 1·NCT07071558·240 enrolled
A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults
Active, not recruiting·GGuangzhou Patronus Biotech Co., Ltd.·Phase 1·NCT06442241·84 enrolled
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
Active, not recruiting·Sanofi logoSanofi·Phase 1/2·NCT06686654·1,530 enrolled
A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older
Active, not recruiting·SShenzhen Shenxin Biotechnology Co., Ltd·Phase 2·NCT07128121·500 enrolled
Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above
Active, not recruiting·SSuzhou Abogen Biosciences Co., Ltd.·Phase 1·NCT07289503·96 enrolled
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Active, not recruiting·Moderna logoModerna·Phase 1·NCT05743881·186 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)